Iron deficiency anemia, inherited hemoglobin disorders (primarily sickle cell disease and thalassemia), and von Willebrand disease are widely regarded as the three most common blood disorders worldwide. Together they affect hundreds of millions of people, from women with heavy periods who feel perpetually exhausted to newborns who inherit altered hemoglobin genes from both parents. Each disorder disrupts a different part of how blood functions, and understanding what they actually do to the body makes it much easier to recognize when something is off.
Iron Deficiency Anemia
Iron deficiency anemia is by far the most common blood disorder on the planet, affecting an estimated one in four people at some point in their lives. It occurs when the body does not have enough iron to produce adequate hemoglobin, the protein inside red blood cells that carries oxygen. Without sufficient hemoglobin, tissues get less oxygen than they need, which is why the hallmark symptoms are fatigue, weakness, pale skin, and shortness of breath during activities that should feel easy.
Your body regulates iron through a hormone called hepcidin, produced in the liver. Hepcidin controls how much iron you absorb from food and how much gets released from storage sites like the liver and spleen. When iron levels drop, hepcidin decreases so the gut can absorb more. When iron levels rise, hepcidin increases and slows absorption. Problems arise when this system gets overwhelmed: chronic blood loss from heavy menstrual periods or gastrointestinal bleeding drains iron faster than the body can replace it, and poor dietary intake or conditions that impair absorption (like celiac disease) compound the deficit.
1PubMed Central. Regulation of the Iron Homeostatic Hormone HepcidinPregnant women face especially high risk. The demands of a growing fetus substantially increase iron requirements, and studies identify age over 35, multiple prior pregnancies, and frequent consumption of tea or coffee as independent risk factors for iron deficiency during pregnancy. Regular prenatal care and iron supplementation are consistently protective.
2PubMed Central. Risk factors for iron deficiency and iron deficiency anemia in pregnant women from plateau region and their impact on pregnancy outcomeDiet matters, too: in a study of pregnant Nigerian women with moderate or severe anemia, daily consumption of green leafy vegetables was linked to substantially lower odds of iron deficiency, while daily consumption of edible kaolin clay was associated with dramatically higher odds.
3PubMed Central. Prevalence of and risk factors for iron deficiency among pregnant women with moderate or severe anaemia in Nigeria: a cross-sectional studyOral iron supplements remain the first-line treatment and work well for most people, though side effects like nausea, constipation, and stomach upset cause some to stop taking them. For patients who cannot tolerate oral iron or whose blood loss outpaces what the gut can absorb, newer intravenous iron preparations offer a safe and underused alternative.
4PubMed Central. Diagnosis and management of iron deficiency anemia in the 21st centuryInherited Hemoglobin Disorders
Sickle cell disease and the thalassemias are the world’s most common inherited blood disorders, and they are frequently grouped together because both involve defective hemoglobin production. Over 330,000 affected infants are born each year, roughly 83 percent with sickle cell disorders and 17 percent with thalassemia. Hemoglobin disorders account for about 3.4 percent of deaths in children under five globally.
5PubMed Central. Global epidemiology of haemoglobin disorders and derived service indicatorsSickle Cell Disease
Sickle cell disease results from a mutation in the gene for beta-globin, one of the building blocks of hemoglobin. The altered hemoglobin (called hemoglobin S) causes red blood cells to stiffen into a crescent or “sickle” shape under low-oxygen conditions. These rigid cells get stuck in small blood vessels, blocking blood flow and triggering episodes of severe pain known as vaso-occlusive crises. Over time, repeated blockages damage organs including the spleen, kidneys, and lungs.
Globally, sickle cell disease causes the highest disability burden among all inherited red blood cell disorders, as measured by disability-adjusted life years. Its incidence has been rising recently, particularly in Africa and the Eastern Mediterranean, while mortality has stayed relatively stable, suggesting that more people are living with the disease but survival has not kept pace with the growing number of cases.
6PubMed. Updated Worldwide Epidemiology of Inherited Erythrocyte DisordersPeople who inherit only one copy of the sickle cell gene (sickle cell trait) generally have no symptoms. There is a well-documented evolutionary reason the gene persists: carrying one copy offers partial protection against malaria, which is why sickle cell trait is most common in populations from malaria-endemic regions of sub-Saharan Africa, the Middle East, and parts of India.
Thalassemia
Thalassemia involves reduced or absent production of one of the two protein chains (alpha or beta) that make up hemoglobin. When one chain is underproduced, the other chain accumulates inside developing red blood cells and damages them, leading to a process called ineffective erythropoiesis: the bone marrow churns out enormous numbers of red blood cell precursors, but most of them die before maturing, worsening the anemia.
7PubMed Central. Ineffective erythropoiesis and thalassemiasAlpha-thalassemia, caused by deletions or mutations affecting the alpha-globin genes, ranges from almost asymptomatic (when only one of four gene copies is affected) to fatal in utero when all four are missing.
8PubMed. Molecular basis of α-thalassemiaBeta-thalassemia is caused by mutations in the beta-globin gene and is broadly split into thalassemia minor (carriers, who are often mildly anemic or symptom-free), thalassemia intermedia (moderate anemia), and thalassemia major (severe anemia requiring lifelong blood transfusions). Beta-thalassemia major comes with serious secondary complications, including enlarged spleen and progressive iron overload from repeated transfusions.
9PubMed Central. Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemiaIron overload is the central long-term threat for transfusion-dependent patients. Each unit of transfused blood deposits iron that the body has no efficient way to excrete. Without chelation therapy (medication that binds excess iron so the body can eliminate it), iron accumulates in the heart and liver, potentially causing fatal heart failure or cirrhosis.
10The BMJ. Diagnosis and management of thalassaemiaThalassemia carriers require no specific treatment, but they should avoid unnecessary iron supplementation because their slightly smaller red blood cells can be misread on lab work as iron deficiency. This is a common and potentially harmful mix-up: a doctor sees small, pale red blood cells, assumes iron deficiency, and prescribes iron, which can do more harm than good in someone who already has normal or elevated iron stores.
10The BMJ. Diagnosis and management of thalassaemiaVon Willebrand Disease
Von Willebrand disease is the most common inherited bleeding disorder. It is caused by a deficiency or dysfunction of von Willebrand factor (VWF), a large protein produced in blood vessel walls and platelet-producing cells. VWF acts as molecular glue at sites of injury: it helps platelets stick to damaged vessel walls and to each other, and it also stabilizes clotting factor VIII in the bloodstream.
11PubMed Central. The role of von Willebrand factor in thrombus formationWhen VWF is deficient or doesn’t work properly, the platelet plug that forms at an injury site is unstable. Mouse studies have shown exactly how unstable: when VWF cannot bind properly to a key platelet receptor, the clots that form fragment and shed material downstream at dramatically higher rates than normal.
12Haematologica. The pivotal role of von Willebrand factor binding to platelet αIIbβ3 in stabilizing the formation of a platelet plug at sites of injuryIn practice, this translates to a pattern of mucosal and skin bleeding. Among adults with moderate or severe forms, the most frequent symptoms are heavy menstrual bleeding (affecting about 85 percent), skin bruising (77 percent), bleeding from minor wounds (77 percent), and bleeding from the mouth or gums (62 percent). Bleeding severity generally worsens from type 1 (partial deficiency of normal VWF) through type 2 (qualitative defects) to type 3 (near-complete absence of VWF).
13PubMed. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand diseaseVon Willebrand disease is the most commonly diagnosed bleeding disorder in women, which makes sense given the prominence of heavy menstrual bleeding as a symptom.
14PubMed Central. Management of pregnant women who have bleeding disordersMany mild cases go undiagnosed for years because the symptoms (easy bruising, gum bleeding, long periods) are easy to dismiss as normal variation. If you have always bled more than seems reasonable after dental work or minor cuts, or if heavy periods have been a lifelong problem that iron supplements never quite fix, it is worth asking your doctor about VWD screening.
The first-line treatment for many patients with type 1 VWD is desmopressin (DDAVP), a synthetic hormone that temporarily boosts the body’s release of stored VWF. It can increase VWF binding activity several-fold, making it effective for planned procedures like dental extractions or to control mild bleeding episodes.
15Haematologica. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand’s disease by flow cytometryFor more severe forms or major surgery, patients receive VWF-containing concentrates. The practical approach to managing replacement therapy involves checking a patient’s baseline VWF activity and factor VIII levels, then matching them with an appropriate concentrate.
16PubMed Central. Von Willebrand disease diagnosis: from complexity to simplicityTelling Similar Conditions Apart
Iron deficiency anemia and thalassemia trait produce strikingly similar lab results: both cause small, pale red blood cells and low hemoglobin. Millions of people carry thalassemia trait without knowing it, and they routinely get misdiagnosed with iron deficiency. The distinction matters because, as noted earlier, giving iron to someone with thalassemia trait can lead to harmful iron accumulation.
Standard blood tests can help distinguish the two. In thalassemia trait, the red blood cell count tends to be high for the degree of anemia, while the cells themselves are disproportionately small. In iron deficiency, the red blood cells tend to vary more in size. Hematologists have developed indices that combine these measurements to improve diagnostic accuracy. One of the most reliable is the red cell distribution width index, which consistently shows better sensitivity and specificity for telling the two apart than simpler measures.
17PubMed Central. Differentiation of beta thalassemia trait from iron deficiency anemia by hematological indices 18Iranian Journal of Pediatric Hematology & Oncology. Evaluation of Twenty Four Discriminant Indices for Differentiating Beta-Thalassemia Trait from Iron Deficiency Anemia in Egyptians
A complicating wrinkle: the two conditions can coexist. Someone with thalassemia trait can also become iron deficient, particularly during pregnancy or with poor dietary intake. When both are present, the hepcidin signaling system gets pulled in opposing directions. Iron deficiency normally suppresses hepcidin to boost absorption, but inflammation or other factors can keep hepcidin elevated even when iron stores are low.
19PubMed Central. Pathways for the regulation of hepcidin expression in anemia of chronic disease and iron deficiency anemia in vivoG6PD Deficiency and Factor V Leiden
These two conditions deserve mention because they rank among the most prevalent blood-related genetic variants in the world, even though they work very differently from the three disorders above.
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is actually the single most common inherited red blood cell enzyme defect worldwide, with the highest incidence in Africa. People with G6PD deficiency are usually fine until they encounter a trigger: certain medications (particularly some antimalarials and antibiotics), fava beans, or infections. The trigger causes a wave of red blood cell destruction, producing sudden anemia, dark urine, and jaundice. Between episodes, most people with G6PD deficiency feel completely normal. The global incidence of inherited red blood cell disorders, including G6PD deficiency, reached roughly 45 million new cases in 2019, and that number has been climbing steadily over three decades.
20PubMed Central. Incidence Trends of Inherited Anemias at the Global, Regional, and National Levels Over Three DecadesFactor V Leiden is a genetic mutation that pushes the blood in the opposite direction: instead of causing bleeding, it increases the risk of clotting. The mutation produces a version of clotting factor V that resists being turned off by the body’s natural anticoagulant system. It is found in roughly 4 to 6 percent of the U.S. population and is associated with a three- to sixfold increase in the risk of venous blood clots, especially in people without an obvious trigger like recent surgery.
21PubMed. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspectiveFactor V Leiden and the prothrombin 20210A mutation together account for the genetic basis of clotting problems in the majority of families with inherited thrombophilia.
22Clinical Chemistry. Factor V Leiden and other coagulation factor mutations affecting thrombotic riskWhy These Disorders Persist
It might seem strange that genes for serious diseases like sickle cell disease and thalassemia remain so common in certain populations. The explanation is malaria. In regions where malaria has historically been a leading killer, carrying one copy of a hemoglobin disorder gene provides meaningful protection against severe malaria infection. This is one of the clearest examples in human biology of a harmful gene being maintained because it also offers a survival advantage. The same evolutionary pressure applies to G6PD deficiency, which is most common in the same malaria-endemic belts.
23PubMed Central. Exploring the protective effects of thalassemia against malaria in Africa: a systematic reviewAs populations migrate and intermix, these genes are increasingly found outside their traditional geographic strongholds. Sickle cell trait, for example, is now common in North America, South America, and Europe, not just in Africa and South Asia. Thalassemia is widespread in Mediterranean, Middle Eastern, and Southeast Asian populations that have spread globally. This makes awareness of these conditions important for clinicians everywhere, not just in malaria zones.
Gene Therapy and New Treatments
For decades, the only potential cure for severe beta-thalassemia or sickle cell disease was a bone marrow transplant from a matched donor, which is risky and unavailable to most patients. That changed with the arrival of CRISPR-based gene editing. In a landmark early trial, researchers used CRISPR-Cas9 to edit a specific genetic switch in patients’ own blood stem cells. The edit reactivated production of fetal hemoglobin, a form of hemoglobin that normally shuts off after birth but can compensate for defective adult hemoglobin. More than a year after treatment, a patient with transfusion-dependent beta-thalassemia no longer needed transfusions, and a patient with sickle cell disease had complete elimination of pain crises.
24PubMed. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-ThalassemiaSince those initial results, CRISPR-based therapies have continued to advance, with researchers exploring both direct correction of the defective hemoglobin gene and reactivation of fetal hemoglobin through different regulatory targets.
25PubMed Central. Advances in β-Thalassemia Gene Therapy: CRISPR/Cas Systems and Delivery InnovationsThese therapies currently require intensive preparation, including chemotherapy to clear the bone marrow before re-infusing the edited cells, and they are extraordinarily expensive. Access remains limited to a small number of specialized centers. But the proof of concept is established: for the first time, there is a realistic path toward curing these diseases at the genetic level rather than managing symptoms for life.
Living with Transfusion-Dependent Thalassemia
For patients who do not have access to gene therapy or transplant, transfusion-dependent beta-thalassemia remains a chronic condition with substantial impact on daily life. A real-world study measuring quality of life in adults with transfusion-dependent thalassemia found that their self-rated health, general well-being, and fatigue levels were all significantly worse than the general population. Fatigue scores were particularly low, reflecting the relentless cycle of rising anemia between transfusions, the side effects of iron chelation, and the time demands of regular hospital visits.
26PubMed Central. Health-related quality of life and economic impacts in adults with transfusion-dependent β-thalassemia: findings from a prospective longitudinal real-world studyThe economic burden compounds the physical one. Regular transfusions, chelation drugs, cardiac monitoring, and specialist visits add up to substantial out-of-pocket costs and lost work time, even in countries with strong public health systems. This is part of why access to curative therapies, whether transplant or gene editing, is not just a medical priority but a health equity issue. Most of the world’s thalassemia patients live in low- and middle-income countries where neither option is realistically available yet.